Following a nine-month investigation, European regulators have found no evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions. This announcement by the European Medicines Agency aligns with the findings of the U.S. Food and Drug Administration. The review was conducted after anecdotal reports of patients experiencing thoughts of self-harm while on these medications. The committee analyzed various data, including clinical trials and post-marketing surveillance, and found no causal association between GLP-1 drugs and the risk of suicidal ideation. The FDA continues to investigate the potential risk, and warnings about monitoring for suicidal thoughts are included in some drug labels.
Source link
No link found between obesity drugs and suicidal thoughts
